Slayback Pharma LLC

Azurity Pharmaceuticals, Inc.

Sandeep Jain

Ajay Kumar Singh

Girish G Kore

Hanimi Reddy Bapatu

Paras P Jain

Girish Kumar Jain

Keerthi Priya

Praveen Kumar Subbappa

Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., C, AUCand/or AUC) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

Pharmaceutical compositions of nilotinib

Solid dispersions of lurasidone or a pharmaceutically acceptable salt thereof are described, as well as pharmaceutical formulations thereof, and methods for making such formulations. Preferably, the solid dispersions are prepared by hot-melt extrusion or spray-drying, and comprise lurasidone with a pharmaceutically acceptable carrier (e.g., hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof). The pharmaceutical composition may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., T, C, AUCand/or AUC) of lurasidone, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

Pharmaceutical compositions of Lurasidone

Pharmaceutical compositions of lurasidone

Growing community of inventors

Madhya Pradesh, India

Sandeep Jain